CKD and ESRD nursing: assessment, interventions, and patient education

Chronic kidney disease (CKD) is an irreversible, progressive decline in kidney function that affects approximately 37 million adults in the United States. It is the ninth leading cause of death nationally, and most patients with CKD are undiagnosed until the disease is advanced. End-stage renal disease (ESRD), classified as stage G5, requires renal replacement therapy — dialysis or transplantation — for survival. Diabetes mellitus type 2 (30–50% of cases) and hypertension (approximately 27%) are the two leading causes. For nursing students, CKD appears consistently on the NCLEX and on every medical-surgical floor. This reference covers the complete clinical picture: staging, pathophysiology, assessment priorities, lab interpretation, nursing interventions, dialysis modalities, complications, patient education, and high-yield NCLEX review points.

CKD stages: KDIGO classification

CKD staging uses the KDIGO (Kidney Disease: Improving Global Outcomes) CGA framework, which classifies every patient by three dimensions: Cause, GFR category, and Albuminuria category. Most nursing resources only cover GFR stages, but the 2024 KDIGO guidelines emphasize that albuminuria is an independent predictor of cardiovascular events and kidney disease progression — understanding both dimensions is essential.

GFR categories (G1–G5)

GFR measures the volume of plasma filtered by the glomeruli per minute. A normal GFR is 90–120 mL/min/1.73 m². As nephrons are destroyed, GFR falls progressively. The average age-related decline after age 40–50 is approximately 0.75–1 mL/min per year; diabetic nephropathy can progress at 10 mL/min per year or faster.

Albuminuria categories (A1–A3)

Albuminuria reflects glomerular damage and is measured using the urine albumin-to-creatinine ratio (ACR). Rising albuminuria independently increases both cardiovascular and kidney disease progression risk, even when GFR is normal.

• A1 (normal to mildly increased): ACR <30 mg/g. Low risk if GFR is preserved.
• A2 (moderately increased): ACR 30–299 mg/g (formerly called “microalbuminuria”). Signals early glomerular injury. Requires ACE inhibitor or ARB therapy to slow progression.
• A3 (severely increased): ACR ≥300 mg/g (formerly called “macroalbuminuria” or overt proteinuria). High risk of rapid progression to ESRD. Aggressive blood pressure and glycemic control are essential.

The combination of GFR category and albuminuria category creates a risk matrix. For example, a patient with G3a/A1 has lower risk than a patient with G3a/A3, even though both have the same GFR. This is why the KDIGO guidelines require both measurements for proper staging.

Pathophysiology: how CKD progresses

CKD progresses through a cycle of nephron loss, compensatory hyperfiltration, and further damage. Understanding this mechanism explains why CKD is irreversible and why early intervention focuses on slowing — rather than reversing — the decline.

The nephron loss cycle

When nephrons are destroyed by the primary disease (diabetes, hypertension, glomerulonephritis), the remaining nephrons compensate by increasing their individual filtration rate. This compensatory hyperfiltration temporarily maintains overall GFR but generates increased intraglomerular pressure that damages the surviving nephrons over time. Each lost nephron accelerates the loss of the next — this is why CKD progression follows a predictable downward trajectory once it reaches a critical threshold.

Uremia

As GFR falls below approximately 15 mL/min, the kidneys can no longer adequately excrete nitrogenous waste products (urea, creatinine, uric acid). These toxins accumulate in the blood, producing the syndrome known as uremia. Uremic symptoms include nausea, vomiting, metallic taste, anorexia, fatigue, pruritus, peripheral neuropathy, and cognitive changes. In severe cases, urea crystallizes on the skin (uremic frost) and accumulates in the pericardial sac (uremic pericarditis).

Cardiovascular consequences

CKD is a cardiovascular disease as much as a kidney disease. The cardiorenal syndrome describes the bidirectional relationship between cardiac and renal dysfunction: kidney disease causes fluid overload, hypertension, anemia, and electrolyte imbalances that stress the heart; cardiac dysfunction reduces renal perfusion, accelerating kidney damage. Patients with CKD are more likely to die of cardiovascular disease than to reach dialysis. This is why cardiovascular risk reduction is a priority at every CKD stage.

Additional mechanisms contributing to cardiovascular damage in CKD include chronic volume overload (from sodium and water retention), left ventricular hypertrophy (from sustained hypertension), accelerated atherosclerosis (from dyslipidemia and chronic inflammation), and vascular calcification (from disturbed calcium-phosphorus metabolism).

Nursing assessment priorities

Assessment of the CKD patient spans multiple body systems because the kidneys regulate fluid balance, electrolytes, acid-base status, red blood cell production, bone metabolism, and blood pressure. A systematic approach ensures nothing is missed.

Fluid status

Monitor daily weights at the same time, with the same scale, in similar clothing — a weight gain of 1 kg (2.2 lbs) over 24 hours represents approximately 1 liter of retained fluid. Assess for peripheral edema (ankles, sacrum in bedbound patients), periorbital edema, jugular venous distension, and pulmonary crackles. Track strict intake and output. In advanced CKD, urine output progressively declines toward oliguria (<400 mL/day) or anuria.

Blood pressure

Hypertension is both a cause and a consequence of CKD. Target blood pressure is generally <130/80 mmHg per current guidelines. Monitor for orthostatic changes, especially in patients on antihypertensives. Report persistent readings above target — uncontrolled hypertension accelerates GFR decline.

Neurological status

Uremic encephalopathy presents as confusion, lethargy, asterixis (flapping tremor of the hands), decreased concentration, and in severe cases, seizures or coma. Peripheral neuropathy causes numbness, tingling, and burning sensations in the extremities, particularly the feet. Restless leg syndrome is common. Assess orientation, mental status, and deep tendon reflexes at each encounter.

Integumentary assessment

Uremic frost appears as fine white or yellowish crystalline deposits on the skin, caused by urea secretion through sweat glands — this is a late finding indicating severe uremia requiring immediate dialysis. Uremic pruritus is intense, generalized itching caused by calcium-phosphorus deposition in the skin, uremic toxins, and secondary hyperparathyroidism. Skin may appear yellowish-brown due to retained urochrome pigments. Assess for excoriations from scratching, ecchymosis from platelet dysfunction, and poor wound healing.

Cardiovascular assessment

Auscultate for pericardial friction rub (uremic pericarditis — a dialysis emergency). Monitor heart rhythm for signs of hyperkalemia: peaked T waves, widened QRS, and eventual sine wave pattern. Assess for signs of fluid overload: S3 heart sound, jugular venous distension, and hypertension. Review the EKG interpretation cheat sheet for rhythm recognition.

Respiratory assessment

Auscultate lung fields for crackles indicating pulmonary edema. Kussmaul respirations (deep, rapid breathing) indicate metabolic acidosis — the kidneys cannot excrete hydrogen ions or regenerate bicarbonate. Monitor oxygen saturation, particularly in patients with concurrent anemia.

Key lab values in CKD

Laboratory monitoring is the cornerstone of CKD management. The following table summarizes key labs, their normal ranges, expected changes in CKD, and the clinical significance for nursing assessment. Use this alongside the nursing lab values cheat sheet and electrolyte imbalances reference.

Priority nursing interventions

Nursing interventions in CKD target the complications that the kidneys can no longer regulate. Every intervention connects back to the pathophysiology: if you understand why the problem occurs, the intervention follows logically.

Fluid management

Restrict fluid intake as ordered — typically 1,000–1,500 mL/day in advanced CKD or dialysis patients. Accurate intake and output tracking is essential. Teach patients to measure fluid intake using a marked container, count ice chips as fluid (approximately half volume), and recognize hidden fluid sources in foods like soup, gelatin, and ice cream. Diuretics (loop diuretics such as furosemide) may be used in earlier stages when the kidneys still respond. Administer diuretics in the morning to prevent nocturia.

Dietary restrictions

Dietary management in CKD requires balancing multiple restrictions simultaneously. A renal dietitian referral is standard of care.

• Sodium: Restrict to <2,000 mg/day to control blood pressure and fluid retention. Teach patients to read labels, avoid processed foods, and use herbs instead of salt.
• Potassium: Restrict in stages G4–G5 and on dialysis to prevent hyperkalemia. High-potassium foods to limit: bananas, oranges, potatoes, tomatoes, avocados, spinach, and salt substitutes (which contain potassium chloride).
• Phosphorus: Restrict to 800–1,000 mg/day. High-phosphorus foods: dairy products, dark colas, processed meats, nuts, and chocolate. Administer phosphate binders (sevelamer, calcium acetate) with meals — they must be taken during eating to bind dietary phosphorus in the gut.
• Protein: Moderate restriction (0.6–0.8 g/kg/day) in pre-dialysis CKD slows progression by reducing the hyperfiltration workload on remaining nephrons. Once on dialysis, protein requirements increase (1.0–1.2 g/kg/day for hemodialysis) because dialysis removes amino acids.

Anemia management

CKD-related anemia results from decreased erythropoietin (EPO) production by damaged kidneys. Treatment includes erythropoiesis-stimulating agents (ESAs) such as epoetin alfa (Epogen, Procrit) and darbepoetin alfa (Aranesp). Target hemoglobin is 10–11.5 g/dL — overshooting above 13 g/dL increases the risk of stroke, hypertension, and vascular access thrombosis. Iron supplementation is often needed concurrently because ESAs increase iron demand. Monitor iron studies (ferritin, transferrin saturation) before starting ESA therapy.

CKD-mineral and bone disorder (CKD-MBD)

CKD-MBD is a distinct complication involving the triad of abnormal calcium-phosphorus metabolism, secondary hyperparathyroidism, and bone disease (renal osteodystrophy). The calcium-phosphorus product (Ca × P) should remain below 55 mg²/dL² — when this product is elevated, calcium and phosphorus precipitate in soft tissues and blood vessels, causing vascular calcification and increasing cardiovascular mortality.

Management includes phosphate binders with meals, active vitamin D supplements (calcitriol) to improve calcium absorption, and calcimimetics (cinacalcet) to suppress PTH secretion directly. Monitor calcium, phosphorus, and PTH levels per KDIGO frequency guidelines — more frequently as CKD advances.

Blood pressure control

ACE inhibitors (lisinopril, enalapril) and ARBs (losartan, valsartan) are the preferred antihypertensives in CKD because they reduce intraglomerular pressure and slow proteinuria progression. Monitor for hyperkalemia (ACE/ARBs reduce potassium excretion) and rising creatinine (a creatinine increase up to 30% from baseline after starting an ACE/ARB is acceptable and expected). Target blood pressure is <130/80 mmHg. Additional agents (calcium channel blockers, diuretics) are frequently needed.

Medication adjustments

The kidneys clear many medications. In CKD, dosing must be adjusted based on GFR to prevent toxicity. Key principles:

• Avoid nephrotoxic agents: NSAIDs, aminoglycosides, IV contrast dye. If contrast is necessary, pre-hydrate with IV normal saline and hold metformin for 48 hours after the procedure to prevent contrast-induced nephropathy.
• Adjust renally cleared medications: digoxin, metformin (contraindicated below GFR 30), certain antibiotics, opioids (morphine metabolites accumulate — use hydromorphone or fentanyl instead).
• Hold ACE/ARBs on dialysis days per provider order if hypotension is a concern during treatment.
• Review all medications (including over-the-counter drugs) at every visit. Patients should avoid potassium-containing salt substitutes and magnesium-containing antacids.

Renal replacement therapy

When GFR falls below approximately 10–15 mL/min and the patient develops symptoms refractory to medical management, renal replacement therapy (RRT) becomes necessary. The three options — hemodialysis, peritoneal dialysis, and kidney transplantation — each have distinct nursing considerations.

AV fistula assessment and care

The arteriovenous (AV) fistula is the preferred hemodialysis access because it has the highest patency rates, lowest infection rates, and best long-term outcomes. It is created by surgically connecting an artery to a vein (typically the radial artery to the cephalic vein in the nondominant arm). The fistula requires 2–6 months to mature before use.

Assessment — the thrill and bruit:

• Thrill: A continuous, palpable vibration (buzzing) felt over the fistula site. Palpate gently with your fingertips. The thrill confirms blood flow through the anastomosis. An absent thrill is an emergency — it may indicate thrombosis.
• Bruit: A continuous, low-pitched humming sound heard with a stethoscope over the fistula site. Auscultate routinely. Absence of the bruit, like absence of the thrill, suggests clotting.

Nursing care for the fistula arm:

• No blood pressure measurements on the fistula arm
• No venipuncture or IV lines in the fistula arm
• No constrictive clothing, watches, or jewelry on the fistula arm
• Do not sleep on the fistula arm
• Elevate the arm if swelling occurs
• Teach the patient to check for thrill daily — if absent, seek immediate medical attention
• Report signs of infection: redness, warmth, swelling, drainage, or fever

Dialysis complications

Hypotension during hemodialysis is the most common complication, occurring when fluid is removed faster than plasma refilling can compensate. Interventions: slow the ultrafiltration rate, place the patient in Trendelenburg position, administer normal saline bolus as ordered. Prevent by ensuring the patient does not exceed their interdialytic weight gain (ideally <2–3 kg between sessions).

Disequilibrium syndrome occurs during or shortly after hemodialysis when rapid removal of solutes from the blood creates an osmotic gradient that pulls water into the brain. Symptoms: headache, nausea, vomiting, restlessness, and in severe cases, seizures. More common during the first few dialysis sessions. Prevent by using shorter, slower initial treatments.

Peritonitis in peritoneal dialysis presents as cloudy dialysate effluent, abdominal pain, and fever. Obtain an effluent sample for culture before starting antibiotics. The effluent WBC count will be >100/μL with >50% neutrophils. Strict aseptic technique during exchanges is the primary prevention strategy.

Complications of CKD

CKD generates a cascade of complications that affect virtually every body system. Each complication is a potential exam question and a clinical assessment priority.

Hyperkalemia

The kidneys excrete approximately 90% of dietary potassium. As GFR declines, potassium accumulates. Serum potassium above 5.5 mEq/L requires intervention; above 6.5 mEq/L is a medical emergency. Cardiac effects progress in a predictable sequence: peaked T waves → flattened P waves → widened QRS → sine wave → cardiac arrest. Immediate treatment includes IV calcium gluconate (stabilizes cardiac membrane), IV insulin with dextrose (shifts potassium intracellularly), and sodium polystyrene sulfonate (Kayexalate) or patiromer for ongoing removal. See the electrolyte imbalances reference for the complete hyperkalemia protocol.

Metabolic acidosis

Damaged kidneys cannot excrete hydrogen ions or regenerate bicarbonate. Chronic metabolic acidosis (serum bicarbonate <22 mEq/L) accelerates muscle wasting, bone loss, and CKD progression. Treatment includes oral sodium bicarbonate supplementation to maintain serum bicarbonate ≥22 mEq/L. Assess for Kussmaul respirations — the respiratory system’s compensatory attempt to blow off CO₂. Review ABG interpretation for acid-base analysis.

Renal osteodystrophy (CKD-MBD bone disease)

The calcium-phosphorus-PTH axis becomes progressively deranged in CKD. The sequence: damaged kidneys cannot activate vitamin D → calcium absorption from the gut decreases → serum calcium falls → parathyroid glands secrete excess PTH (secondary hyperparathyroidism) → PTH pulls calcium from bones → bones weaken. Simultaneously, phosphorus accumulates because the kidneys cannot excrete it, further suppressing calcium and stimulating PTH. The clinical result is bone pain, pathologic fractures, and soft tissue calcification.

Anemia of CKD

Healthy kidneys produce approximately 90% of the body’s erythropoietin. As renal mass decreases, EPO production falls, causing a normocytic, normochromic anemia that worsens with each CKD stage. Symptoms include fatigue, pallor, exercise intolerance, and dyspnea on exertion. Anemia also worsens cardiac workload, contributing to left ventricular hypertrophy.

Cardiovascular disease

CKD patients have a 10–20 times higher cardiovascular mortality risk compared to the general population. Contributing factors include chronic hypertension, volume overload, LVH, dyslipidemia, vascular calcification from disturbed mineral metabolism, and chronic inflammation. Uremic pericarditis presents as pleuritic chest pain relieved by leaning forward, with a pericardial friction rub on auscultation — this is an absolute indication for urgent dialysis.

AKI on CKD

Patients with CKD are highly vulnerable to acute kidney injury from dehydration, infection, nephrotoxic medications, or IV contrast. An episode of AKI in a CKD patient can cause a permanent, stepwise decline in baseline GFR. Prevention is critical: maintain hydration during illness, avoid NSAIDs, and ensure pre-hydration before contrast procedures. See the AKI nursing reference for complete assessment and management details.

Uremic encephalopathy

Accumulation of uremic toxins impairs central nervous system function. Early signs include difficulty concentrating, irritability, and sleep disturbances. Progression leads to asterixis, myoclonus, confusion, and eventually seizures or coma. This is an indication for emergent dialysis. Monitor neurological status closely in patients with GFR <15 mL/min.

Patient education

Effective patient education is a core nursing responsibility in CKD management. Patients who understand their disease and its management have better outcomes, slower progression, and fewer emergency hospitalizations.

Dietary modifications

Teach patients the renal diet essentials using simple, practical guidance rather than abstract nutrient targets:

• Low sodium: Avoid canned soups, processed meats, fast food, and restaurant meals. Use herbs, garlic, and lemon for flavor. Read labels — aim for <600 mg sodium per meal.
• Low potassium (stages G4–G5): Limit bananas, oranges, potatoes, tomatoes, and salt substitutes. Leaching potassium from vegetables by soaking sliced pieces in water for 2+ hours before cooking can reduce potassium content by up to 50%.
• Low phosphorus: Avoid dark colas, dairy products in excess, processed cheese, and chocolate. Take phosphate binders at the start of every meal containing protein.
• Protein management: Follow the provider’s protein recommendation — too much protein accelerates kidney damage in pre-dialysis CKD, but too little causes malnutrition, especially once on dialysis.

Fluid management

For patients on fluid restriction, teach practical strategies: use small cups, suck on ice chips or hard candy to relieve thirst, rinse the mouth without swallowing, keep a fluid intake log, and distribute allowed fluid evenly throughout the day. Weigh daily and report weight gains greater than 2 lbs (approximately 1 kg) overnight.

Medication adherence

Patients with CKD typically manage multiple medications: antihypertensives, phosphate binders, ESAs, iron supplements, bicarbonate tablets, and potentially dozens of other prescriptions. Teach the purpose of each medication, the importance of timing (phosphate binders must be taken with food), and which over-the-counter medications to avoid (NSAIDs, magnesium-containing antacids, potassium supplements). A pill organizer and medication list kept in the wallet are simple, effective adherence tools.

Blood pressure monitoring

Teach home blood pressure monitoring technique: sit quietly for 5 minutes, feet flat on the floor, arm supported at heart level, use the same arm consistently (avoiding the fistula arm). Record readings in a log and bring it to every provider visit. Report readings consistently above 130/80 mmHg or symptoms such as headache, vision changes, or chest pain.

Dialysis access care

For patients with an AV fistula or graft, teach daily self-assessment: feel for the thrill several times per day, report any change or absence immediately. Keep the access site clean and dry. Avoid carrying heavy objects with the access arm. For PD patients, teach strict hand hygiene and aseptic technique during exchanges, proper catheter exit-site care, and recognition of peritonitis signs (cloudy effluent, abdominal pain, fever).

When to seek emergency care

Educate patients and families to seek immediate care for: sudden shortness of breath, chest pain, severe headache with confusion, muscle weakness with irregular heartbeat (hyperkalemia), no urine output for 12+ hours, fever with dialysis access redness or PD effluent cloudiness, or seizure activity.

NCLEX tips

• CKD is defined as kidney damage or GFR <60 mL/min for ≥3 months. The 3-month duration distinguishes CKD from AKI. If a question stem describes renal impairment for less than 3 months, consider AKI.
• KDIGO staging requires both GFR AND albuminuria. A patient with GFR 55 (G3a) and ACR 350 (A3) has higher risk than a patient with GFR 55 and ACR 20 (A1), even though the GFR is identical.
• The top two causes of CKD are diabetes and hypertension. If an NCLEX question asks about CKD risk reduction, think glucose control and blood pressure management first.
• Phosphate binders must be taken WITH meals — not before, not after. They work by binding dietary phosphorus in the GI tract. Taking them on an empty stomach is ineffective.
• ACE inhibitors and ARBs are renoprotective in CKD. They reduce intraglomerular pressure and slow proteinuria. A creatinine rise up to 30% after initiation is expected and acceptable — do not discontinue.
• ESA target hemoglobin is 10–11.5 g/dL. Raising hemoglobin above 13 g/dL with ESAs increases the risk of stroke and cardiovascular events. If a question asks about holding epoetin alfa, check the hemoglobin level.
• AV fistula assessment = thrill (palpate) + bruit (auscultate). Absence of either indicates potential thrombosis — report immediately. Never perform BP measurement, venipuncture, or IV insertion in the fistula arm.
• Hypotension is the most common hemodialysis complication. Interventions: lower the ultrafiltration rate, Trendelenburg position, IV normal saline bolus.
• Peritonitis in PD = cloudy effluent + abdominal pain + fever. Always obtain effluent cultures before starting antibiotics. Strict aseptic technique is the primary prevention measure.
• Uremic pericarditis requires emergent dialysis. If you hear a pericardial friction rub in a CKD patient, think dialysis immediately — this is the same principle tested in AKI questions. See the AKI nursing reference for related concepts.
• Hyperkalemia EKG progression: peaked T waves → absent P waves → widened QRS → sine wave. Calcium gluconate stabilizes the membrane but does not lower potassium. Insulin with dextrose is the intracellular shift intervention.
• Contrast-induced nephropathy prevention: Pre-hydrate with IV normal saline, hold nephrotoxic medications, hold metformin for 48 hours post-procedure. Patients with existing CKD are at highest risk.

References

• Chronic Kidney Disease (Nursing). StatPearls [Internet]. National Library of Medicine. NCBI Bookshelf NBK568778.
• KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International. 2024;105(4S):S1–S372.
• Chronic Kidney Disease in the United States, 2023. Centers for Disease Control and Prevention. National Chronic Kidney Disease Fact Sheet.
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Chronic Kidney Disease. NIH Publication.
• Chronic Kidney Disease. StatPearls [Internet]. National Library of Medicine. NCBI Bookshelf NBK535404.
• Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-MBD. Kidney International Supplements. 2017;7(1):1–59.